In an important update for those within the Parkinson's community in British Columbia, two critical Parkinson's pharmaceuticals, Movapo and Kynmobi, are being discontinued by their respective distribution companies, Palladin and Sunovion. Movapo has already ceased supply, and Kynmobi will follow suit on September 30, 2023.

Movapo and Kynmobi, both forms of Apomorphine, a potent dopamine agonist, are unique in their administration. Movapo is injected, while Kynmobi is taken as sublingual strips. While not widely prescribed, they function as 'rescue' medications for a small but critical number of patients, supplementing oral levodopa doses and extending symptom relief periods.

The pharmaceutical companies involved have indicated that limited demand for these medications necessitated their discontinuation. This decision presents considerable challenges for dependent patients, who now face a scarcity of alternative options. While importing Movapo from the USA or Europe is under consideration, the feasibility of such an approach is yet to be confirmed. Regrettably, Kynmobi, produced by a Canadian company, will not be available from other sources.

This situation brings to the forefront a critical issue on Parkinson Society BC’s advocacy platform - the urgent need for more healthcare professionals specializing in Parkinson's disease. Long wait times, often spanning 6 to 24 months to see movement disorder specialists, pose a serious impediment to optimal patient care.

We understand the gravity of this situation for those impacted and will continue to advocate for better healthcare resources and explore all potential avenues to address this concern. Please stay tuned for further updates.